{"id":250107,"date":"2023-01-10T00:00:00","date_gmt":"2023-01-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0061-biopharma-acute-myeloid-leukemia-epidemiology\/"},"modified":"2026-04-18T11:26:21","modified_gmt":"2026-04-18T11:26:21","slug":"epidon0095-biopharma-acute-myeloid-leukemia-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0095-biopharma-acute-myeloid-leukemia-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Acute Myeloid Leukemia &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of <abbr data-abbreviation-entity=\"4729\" title=\"acute myeloid leukemia\">AML<\/abbr> comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of <abbr title=\"age-related macular degeneration\">AML<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"age-related macular degeneration\">AML<\/abbr> forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"age-related macular degeneration\">AML<\/abbr> and the number of new diagnoses of <abbr title=\"age-related macular degeneration\">AML<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"age-related macular degeneration\">AML<\/abbr>, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"age-related macular degeneration\">AML<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total number of diagnosed AML incident cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"acute myeloid leukemia\">AML<\/abbr> populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Cytogenetic risk<\/li>\n<li>Prevalent cases<\/li>\n<li>Drug-treatable populations<\/li>\n<li>Drug-treated populations<\/li>\n<li>FLT3 mutations<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250107","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250107\/revisions"}],"predecessor-version":[{"id":555970,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250107\/revisions\/555970"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}